BH.IMMUN&BIO | FERMENTA BIOTECH | BH.IMMUN&BIO/ FERMENTA BIOTECH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.7 | -23.3 | - | View Chart |
P/BV | x | 1.5 | 1.7 | 89.2% | View Chart |
Dividend Yield | % | 0.0 | 0.7 | - |
BH.IMMUN&BIO FERMENTA BIOTECH |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
FERMENTA BIOTECH Mar-23 |
BH.IMMUN&BIO/ FERMENTA BIOTECH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 280 | 18.5% | |
Low | Rs | 21 | 103 | 19.8% | |
Sales per share (Unadj.) | Rs | 10.3 | 121.3 | 8.5% | |
Earnings per share (Unadj.) | Rs | -3.9 | -18.6 | 20.8% | |
Cash flow per share (Unadj.) | Rs | -3.8 | -8.8 | 43.4% | |
Dividends per share (Unadj.) | Rs | 0 | 1.25 | 0.0% | |
Avg Dividend yield | % | 0 | 0.7 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 104.4 | 19.6% | |
Shares outstanding (eoy) | m | 43.18 | 28.86 | 149.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 1.6 | 221.4% | |
Avg P/E ratio | x | -9.4 | -10.3 | 90.8% | |
P/CF ratio (eoy) | x | -9.5 | -21.9 | 43.4% | |
Price / Book Value ratio | x | 1.8 | 1.8 | 96.4% | |
Dividend payout | % | 0 | -6.7 | 0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 5,531 | 28.2% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 579 | 26.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 3,499 | 12.7% | |
Other income | Rs m | 11 | 77 | 13.8% | |
Total revenues | Rs m | 457 | 3,576 | 12.8% | |
Gross profit | Rs m | -161 | -99 | 161.5% | |
Depreciation | Rs m | 2 | 282 | 0.7% | |
Interest | Rs m | 71 | 214 | 33.0% | |
Profit before tax | Rs m | -223 | -519 | 42.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 17 | -334.9% | |
Profit after tax | Rs m | -166 | -536 | 31.1% | |
Gross profit margin | % | -36.0 | -2.8 | 1,267.2% | |
Effective tax rate | % | 25.3 | -3.2 | -780.3% | |
Net profit margin | % | -37.3 | -15.3 | 243.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 2,737 | 13.1% | |
Current liabilities | Rs m | 940 | 2,294 | 41.0% | |
Net working cap to sales | % | -130.6 | 12.7 | -1,031.6% | |
Current ratio | x | 0.4 | 1.2 | 31.9% | |
Inventory Days | Days | 85 | 58 | 146.7% | |
Debtors Days | Days | 1,135 | 434 | 261.4% | |
Net fixed assets | Rs m | 1,262 | 3,650 | 34.6% | |
Share capital | Rs m | 432 | 144 | 299.3% | |
"Free" reserves | Rs m | 450 | 2,870 | 15.7% | |
Net worth | Rs m | 882 | 3,014 | 29.3% | |
Long term debt | Rs m | 0 | 836 | 0.0% | |
Total assets | Rs m | 1,620 | 6,387 | 25.4% | |
Interest coverage | x | -2.2 | -1.4 | 150.9% | |
Debt to equity ratio | x | 0 | 0.3 | 0.0% | |
Sales to assets ratio | x | 0.3 | 0.5 | 50.3% | |
Return on assets | % | -5.9 | -5.0 | 117.4% | |
Return on equity | % | -18.9 | -17.8 | 106.1% | |
Return on capital | % | -17.2 | -7.9 | 217.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 14.5 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 65 | NA | - | |
Fx inflow | Rs m | 0 | 1,597 | 0.0% | |
Fx outflow | Rs m | 65 | 608 | 10.6% | |
Net fx | Rs m | -65 | 989 | -6.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 1,167 | 9.3% | |
From Investments | Rs m | 5 | -563 | -0.8% | |
From Financial Activity | Rs m | -147 | -408 | 36.1% | |
Net Cashflow | Rs m | -34 | 196 | -17.1% |
Indian Promoters | % | 59.3 | 54.5 | 108.8% | |
Foreign collaborators | % | 0.0 | 7.6 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 37.9 | 107.4% | |
Shareholders | 35,313 | 15,178 | 232.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | DIL LIMITED | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.23% | -0.06% | 0.31% |
1-Month | -2.23% | 6.04% | 0.08% |
1-Year | 28.97% | 18.59% | 54.11% |
3-Year CAGR | -13.27% | -18.74% | 14.46% |
5-Year CAGR | 30.36% | -6.51% | 20.04% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the DIL LIMITED share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of DIL LIMITED the stake stands at 62.1%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of DIL LIMITED.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
DIL LIMITED paid Rs 1.3, and its dividend payout ratio stood at -6.7%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of DIL LIMITED.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended higher.